van Rhijn B - Search Results

1

Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive bladder cancer.

Kamat AM, Vlahou A, Taylor JA, Hudson ML, Pesch B, Ingersoll MA, Todenhöfer T, van Rhijn B, Kassouf W, Barton Grossman H, Behrens T, Chandra A, Goebell PJ, Palou J, Sanchez-Carbayo M, Schmitz-Dräger BJ. Kamat AM, et al. Among authors: van rhijn b. Urol Oncol. 2014 Oct;32(7):1069-77. doi: 10.1016/j.urolonc.2014.06.017. Epub 2014 Oct 11. Urol Oncol. 2014. PMID: 25306288 Review.

2

Presence of carcinoma in situ and high 2C-deviation index are the best predictors of invasive transitional cell carcinoma of the bladder in patients with high-risk Quanticyt.

van Rhijn BW, van der Poel HG, Boon ME, Debruyne FM, Schalken JA, Witjes JA. van Rhijn BW, et al. Among authors: van der poel hg. Urology. 2000 Mar;55(3):363-7. doi: 10.1016/s0090-4295(99)00460-4. Urology. 2000. PMID: 10699611

3

Consecutive quantitative cytology in bladder cancer.

van der Poel HG, van Rhijn BW, Peelen P, Debruyne FM, Boon ME, Schalken JA. van der Poel HG, et al. Among authors: van rhijn bw. Urology. 2000 Oct 1;56(4):584-8. doi: 10.1016/s0090-4295(00)00726-3. Urology. 2000. PMID: 11018610

4

Urine markers for bladder cancer surveillance: a systematic review.

van Rhijn BW, van der Poel HG, van der Kwast TH. van Rhijn BW, et al. Eur Urol. 2005 Jun;47(6):736-48. doi: 10.1016/j.eururo.2005.03.014. Epub 2005 Mar 23. Eur Urol. 2005. PMID: 15925067 Review.

5

Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative?

de Bekker-Grob EW, van der Aa MN, Zwarthoff EC, Eijkemans MJ, van Rhijn BW, van der Kwast TH, Steyerberg EW. de Bekker-Grob EW, et al. BJU Int. 2009 Jul;104(1):41-7. doi: 10.1111/j.1464-410X.2008.08323.x. Epub 2008 Dec 19. BJU Int. 2009. PMID: 19500328 Free article. Clinical Trial.

6

Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy.

van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, Witjes JA, Zlotta AR. van Rhijn BW, et al. Eur Urol. 2009 Sep;56(3):430-42. doi: 10.1016/j.eururo.2009.06.028. Epub 2009 Jun 26. Eur Urol. 2009. PMID: 19576682 Review.

7

BCAN Think Tank session 1: Overview of risks for and causes of bladder cancer.

Zlotta AR, Cohen SM, Dinney C, Droller M, van der Kwast TH, van Rhijn BW, Bochner B, Ameil G, Jewett MA. Zlotta AR, et al. Among authors: van rhijn bw, van der kwast th. Urol Oncol. 2010 May-Jun;28(3):329-33. doi: 10.1016/j.urolonc.2009.10.011. Urol Oncol. 2010. PMID: 20439032

8

Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors.

Alkhateeb SS, Van Rhijn BW, Finelli A, van der Kwast T, Evans A, Hanna S, Vajpeyi R, Fleshner NE, Jewett MA, Zlotta AR. Alkhateeb SS, et al. J Urol. 2010 Jul;184(1):81-6. doi: 10.1016/j.juro.2010.03.022. Epub 2010 May 15. J Urol. 2010. PMID: 20478593

9

Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer.

van Rhijn BW, Zuiverloon TC, Vis AN, Radvanyi F, van Leenders GJ, Ooms BC, Kirkels WJ, Lockwood GA, Boevé ER, Jöbsis AC, Zwarthoff EC, van der Kwast TH. van Rhijn BW, et al. Eur Urol. 2010 Sep;58(3):433-41. doi: 10.1016/j.eururo.2010.05.043. Epub 2010 Jun 9. Eur Urol. 2010. PMID: 20646825

10

Optimal timing of radical cystectomy in T1 high-grade bladder cancer.

Boström PJ, Alkhateeb S, van Rhijn BW, Kuk C, Zlotta AR. Boström PJ, et al. Expert Rev Anticancer Ther. 2010 Dec;10(12):1891-902. doi: 10.1586/era.10.183. Expert Rev Anticancer Ther. 2010. PMID: 21110756

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

297 results

Search Page